Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Apr 7, 2009; 15(13): 1594-1599
Published online Apr 7, 2009. doi: 10.3748/wjg.15.1594
Published online Apr 7, 2009. doi: 10.3748/wjg.15.1594
Table 2 Medications taken by study patients at time of the commencement of MMF therapy
| CD patients n = 9 | UC/IBDU patients n = 5 | |
| 5-ASA | ||
| Current | 88.9% (8/9) | 100% (5/5) |
| Steroids | ||
| Current | 55.5% (5/9) | 100% (5/5) |
| Intolerant | 22.2% (2/9) | 0% |
| AZA/6MP | ||
| Intolerant | 88.8% (8/9) | 100% (5/5) |
| Methotrexate | ||
| Ineffective | 33.3% (3/9) | N/A |
| Intolerant | 11.1% (1/9) | |
| Refused | 33.3% (3/9) | |
| Antibiotics | ||
| Ineffective | 33.3% (3/9) | N/A |
| Intolerant | 11.1% (1/9) | |
| Infliximab | ||
| Current | 0% | 0% |
| Ineffective | 44.4% (4/9) | 40% (2/5) |
| Intolerant | 22.2% (2/9) | 0% |
- Citation: Tan T, Lawrance IC. Use of mycophenolate mofetil in inflammatory bowel disease. World J Gastroenterol 2009; 15(13): 1594-1599
- URL: https://www.wjgnet.com/1007-9327/full/v15/i13/1594.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.1594